Gilead Sciences Inc.
0
0
0%

Financials

Income statement

Fundamentals currency is USD
Fiscal date 2024 2023 2022 2021
Total reported revenue 24.5B 27.1B 27.3B 27.3B
Cost of revenue 5.3B 6.5B 5.7B 6.6B
Gross profit 19.2B 20.6B 21.6B 20.7B
Operating expense
Research & development 5.0B 5.7B 5.0B 4.6B
Selling general and admin 5.2B 6.1B 5.7B 5.2B
Other operating expenses
Operating income 9.0B 8.8B 11.0B 10.9B
Non operating interest income
Income 239.5M
Expense 832.9M 944M 935M 1.0B
Other income expense -7.8B -1.0B -4.2B -1.6B
Pretax income 588.2M 6.9B 5.8B 8.3B
Tax provision 179.9M 1.2B 1.2B 2.1B
Net income 409.2M 5.6B 4.6B 6.2B
Basic EPS 0.4 4.5 3.7 5.0
Diluted EPS 0.4 4.5 3.6 4.9
Basic average shares 1.1B 1.3B 1.3B 1.3B
Diluted average shares 1.1B 1.3B 1.3B 1.3B
EBITDA 11.6B 11.7B 12.5B 12.3B
Net income from continuing op. 409.2M 5.6B 4.6B 6.2B
Minority interests 0 52M 26M 24M
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Pre-market opens in 2 hours 27 minutes

05:32
00:00
08:55
17:35
23:59

Trading Hours (Monday - Friday):

Pre-market
08:00 - 08:55
Main market
08:55 - 17:35
Post-market
17:35 - 17:50
All times are displayed in the Europe/Vienna timezone (CET, UTC+01:00).